SurgiMab is a leading brand specializing in near-infrared fluorescence imaging for tumor visualization during surgery. Their innovative products and services provide oncology surgeons with real-time guidance, allowing for more precise and comprehensive tumor resection. Using SurgiMab's tumor-specific molecules, surgeons can achieve a clear-cut image of tumors, enabling them to perform radical surgery.

This fluorescence-guided surgery not only improves patient outcomes but also helps lower healthcare costs. SurgiMab's technology is based on tumor-specific antibodies conjugated to a near-infrared fluorescent dye. This injectable dye targets tumor surface markers, revealing micro-tumors and enabling real-time evaluation of tumor margins.

It's particularly effective in detecting small-size tumor nodules that may be invisible to the naked eye. Their solutions also aid in cancer staging and screening, providing surgeons with real-time tumor assessment for both surgery and diagnosis. With SurgiMab, surgeons can transform a hidden threat into a visible target, ensuring complete tumor resection and the preservation of important structures.

Trust SurgiMab for precise tumor detection and visualization, leading to improved patient outcomes in cancer surgery